Elanco Animal Health Incorporated (NYSE:ELAN) Receives $16.71 Consensus Price Target from Analysts

Elanco Animal Health Incorporated (NYSE:ELAN) has been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $17.29.

Several equities research analysts recently weighed in on the stock. TheStreet upgraded shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a research report on Friday, February 23rd. Barclays boosted their price target on shares of Elanco Animal Health from $19.00 to $23.00 and gave the stock an “overweight” rating in a research report on Thursday. Morgan Stanley boosted their price target on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Finally, The Goldman Sachs Group boosted their price target on shares of Elanco Animal Health from $12.50 to $14.00 and gave the stock a “sell” rating in a research report on Tuesday, February 27th.

Insiders Place Their Bets

In related news, Director R David Hoover bought 20,000 shares of the stock in a transaction dated Wednesday, March 6th. The stock was purchased at an average cost of $16.14 per share, with a total value of $322,800.00. Following the completion of the purchase, the director now owns 185,000 shares of the company’s stock, valued at $2,985,900. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.57% of the stock is owned by insiders.

Institutional Trading of Elanco Animal Health

Several institutional investors and hedge funds have recently modified their holdings of the stock. Twin Tree Management LP grew its stake in Elanco Animal Health by 134.1% in the first quarter. Twin Tree Management LP now owns 310,161 shares of the company’s stock worth $5,049,000 after purchasing an additional 177,671 shares in the last quarter. Picton Mahoney Asset Management lifted its holdings in shares of Elanco Animal Health by 2.5% in the 1st quarter. Picton Mahoney Asset Management now owns 271,917 shares of the company’s stock worth $4,426,000 after buying an additional 6,647 shares during the period. State Board of Administration of Florida Retirement System grew its position in shares of Elanco Animal Health by 5.2% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 506,292 shares of the company’s stock worth $8,242,000 after buying an additional 24,966 shares in the last quarter. Russell Investments Group Ltd. increased its stake in shares of Elanco Animal Health by 32.8% during the first quarter. Russell Investments Group Ltd. now owns 46,571 shares of the company’s stock valued at $758,000 after buying an additional 11,490 shares during the period. Finally, Qsemble Capital Management LP bought a new stake in shares of Elanco Animal Health in the first quarter valued at about $340,000. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 1.9 %

Elanco Animal Health stock opened at $17.21 on Friday. The stock has a market cap of $8.50 billion, a P/E ratio of -6.88, a PEG ratio of 1.42 and a beta of 1.34. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.75 and a quick ratio of 1.35. Elanco Animal Health has a 1 year low of $7.88 and a 1 year high of $17.43. The firm’s 50 day moving average price is $15.00 and its 200-day moving average price is $14.06.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, May 8th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.08. Elanco Animal Health had a negative net margin of 27.87% and a positive return on equity of 6.44%. The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter in the previous year, the business posted $0.45 earnings per share. Elanco Animal Health’s quarterly revenue was down 4.1% on a year-over-year basis. On average, equities analysts predict that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.